Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Substudy 3 of a phase 2 umbrella trial of investigational agents plus pembrolizumab in previously anti-PD-(L)1-treated advanced non-small cell lung cancer
2020-001629-29Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of pembrolizumab, mk-4830 and omaveloxolone in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoint: Objective Response Rate. Started Sep 2020; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-001629-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001629-29.